RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $262
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated LGND | 0.00 |
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:
LGND) with a Outperform and raises the price target from $252 to $262.